Geoffrey Duyk
Partner, Managing Director @ TPG Biotech
Tampa, United States
Geoffrey Duyk is a Series B investor at TPG Biotech in Tampa focused on Biotechnology and Medical. Dr. Geoffrey Duyk was a member of the Board from May 2006 through May 2011, and re-joined the Board in May 2012. Dr. Duyk is a partner of TPG Growth, LLC, an affiliate of TPG Biotechnology Partners II, L.P.Previously, he served on the board of directors and was President of Research and Development at Exelixis, Inc., a biopharmaceutical companyfocusing on drug discovery, from 1996 to 2003.Prior to Exelixis, Dr. Duyk was Vice President of Genomics and one of the founding scientific staff at Millennium Pharmaceuticals, from 1993 to 1996.Before that, Dr. Duyk was an Assistant Professor at Harvard Medical School in the Department of Genetics and Assistant Investigator of the Howard Hughes Medical Institute.Dr. Duyk currently serves on the boards of directors of several private companies and the non-profit Wesleyan University Board of Trustees. He served on the board of directors of Agria Corporation from August 2007 to May 2009, Cardiovascular Systems, Inc. (formerly Replidyne, Inc.) from 2004 to February 2009, Exelixis, Inc. from 1996 to 2003. Dr. Duyk holds a Bachelor of Arts degree in Biology from Wesleyan University and Doctor of Philosophy and Medicine degrees from Case Western Reserve University.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 36%
Last updated:
For AI agents: llms.txt
Industries Geoffrey Duyk invests in
Stages Geoffrey Duyk invests in
Countries Geoffrey Duyk invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Series A
- $10M–$20M
- Series B
- $15M–$70M
- Series C
- $15M–$100M
Investment Focus
Industry
- Biotechnology 5 (45%)
- Medical 4 (36%)
- Chemical 2 (18%)
- CleanTech 2 (18%)
- Health Care 2 (18%)
Stage
- Series B 3 (27%)
- Series C 3 (27%)
- Series A 2 (18%)
- Seed 1 (9%)
- Funding Round 1 (9%)
Country
- United States 4 (36%)
- Japan 1 (9%)
- France 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| LinKinVax operates as a clinical-stage biotechnology company. LinKinVax is developing an innovative protein-based vaccine platform that can accelerate availability of vaccines by leveraging the research conducted at the Vaccine Research Institute (VRI). | $5M / Seed / Feb 10, 2022 | ||
| DNAnexus develops a cloud platform and global network designed for scientific collaboration and accelerated discovery. It provides security, scalability, and collaboration for enterprises and organizations that are pursuing genomic-based approaches to health in order to accelerate medical discovery. DNAnexus is supporting customers around the worldthat are tackling some of the most challenging and exciting opportunities in human health.The company was founded in 2009 and is based in Mountain View, California. | $15M / Series C / Jan 03, 2014 | ||
| DNAnexus develops a cloud platform and global network designed for scientific collaboration and accelerated discovery. It provides security, scalability, and collaboration for enterprises and organizations that are pursuing genomic-based approaches to health in order to accelerate medical discovery. DNAnexus is supporting customers around the worldthat are tackling some of the most challenging and exciting opportunities in human health.The company was founded in 2009 and is based in Mountain View, California. | $15M / Series B / Oct 12, 2011 | ||
| Aerie Pharmaceuticals is a biotechnology company that engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of ophthalmic diseases.The company was founded in 2005 and is headquartered in Bridgewater, New Jersey with research facilities in Research Triangle Park, North Carolina.AeriePharmaceuticals, Inc. is a former subsidiary of Duke University Medical Center. | $41.4M / Series B / Mar 07, 2011 | ||
| Elevance Renewable Sciences is a transforming natural, renewable oils into high-performing specialty products and materials, Elevance is uniquely positioned to meet consumer demand in a market exceeding $100 billion annually in these segments: Performance waxes, NatureWax products, Personal care products, Antimicrobials, Detergents, cleaners andsolvents. | $100M / Series C / Dec 21, 2010 | ||
| Amyris Biotechnologies creates renewable products that focus on fuels and chemicals that provide no-compromise sustainable alternatives to a broad range of petroleum-sourced products. It uses an industrial synthetic biology platform that applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and producespecialty ingredients and consumer products. Its technology creates products that support biopharmaceutical drug discovery and production, from cosmetic emollients and fragrances to fuels, solvents, lubricants, and nutraceuticals. | $41.8M / Series C / Oct 01, 2009 | ||
| Amyris Biotechnologies creates renewable products that focus on fuels and chemicals that provide no-compromise sustainable alternatives to a broad range of petroleum-sourced products. It uses an industrial synthetic biology platform that applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and producespecialty ingredients and consumer products. Its technology creates products that support biopharmaceutical drug discovery and production, from cosmetic emollients and fragrances to fuels, solvents, lubricants, and nutraceuticals. | $21M / Series B / Aug 14, 2008 | ||
| JCR Pharmaceuticals is a Japan-based company primarily engaged in the pharmaceutical business, as well as the medical and research equipment business. The Pharmaceutical business engages in the research, production, purchase and sale of medical drugs and pharmaceutical raw materials. The Medical and Research Equipment business engages in thepurchase and sale of the medical and research equipment. | Mar 12, 2008 | ||
| Amyris Biotechnologies creates renewable products that focus on fuels and chemicals that provide no-compromise sustainable alternatives to a broad range of petroleum-sourced products. It uses an industrial synthetic biology platform that applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and producespecialty ingredients and consumer products. Its technology creates products that support biopharmaceutical drug discovery and production, from cosmetic emollients and fragrances to fuels, solvents, lubricants, and nutraceuticals. | $70M / Series B / Sep 19, 2007 | ||
| Amyris Biotechnologies creates renewable products that focus on fuels and chemicals that provide no-compromise sustainable alternatives to a broad range of petroleum-sourced products. It uses an industrial synthetic biology platform that applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and producespecialty ingredients and consumer products. Its technology creates products that support biopharmaceutical drug discovery and production, from cosmetic emollients and fragrances to fuels, solvents, lubricants, and nutraceuticals. | $20M / Series A / Oct 12, 2006 | ||
| See all 11 investments → | |||
Co-Investors
About TPG Biotech
TPG Biotech is part of the growth equity and venture investment platform of TPG, the global private investment firm. TPG Biotech targets investments in pharmaceutical discovery and development, medical technology, diagnostics, healthcare and pharmaceutical services, life sciences, as well as industrial applications of biotechnology. TPG Biotechhas access to the broader resources of TPG.
TPG Biotech Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Eran Nadav
Managing Director
|
|||
Jim Coulter
Co-Founder
|
|||
|
Kelvin L. Davis
Co-Founder
|
|||
Kevin Lind
Lead Underwriter
|
|||
William S. Price
Co-Founder
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Geoffrey Duyk invest in?
Geoffrey Duyk invests primarily in Biotechnology, Medical and Chemical startups, most often at Series B and Series C stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Geoffrey Duyk invest in?
Geoffrey Duyk typically joins rounds of $10M–$20M at Series A, $15M–$70M at Series B and $15M–$100M at Series C. These are whole funding-round sizes, not Geoffrey Duyk's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Geoffrey Duyk took part in.
How do I contact Geoffrey Duyk?
Public channels for Geoffrey Duyk include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Geoffrey Duyk last invest?
The most recent investment recorded for Geoffrey Duyk closed in Feb 2022. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
